Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial

Authors

W. Fraser Symmans (ORCID: https://orcid.org/0000-0002-1526-184X)
Fabrice André (ORCID: https://orcid.org/0000-0001-5795-8357)
Thomas Filleron (ORCID: https://orcid.org/0000-0003-0724-0659)
Pascal Boucher
Kevin C Tran (ORCID: https://orcid.org/0000-0002-8162-4477)
Magali Lacroix‐Triki (ORCID: https://orcid.org/0000-0002-6641-8536)
Amélie Lusque (ORCID: https://orcid.org/0000-0001-9691-5536)
Florence Dalenc (ORCID: https://orcid.org/0000-0002-9854-4182)
Frédérique Penault‐Llorca (ORCID: https://orcid.org/0000-0002-4279-5492)
Jérôme Lemonnier (ORCID: https://orcid.org/0000-0002-8821-2168)
Lili Du
Thomas Bachelot
Rick Baehner

Institutions

The University of Texas MD Anderson Cancer Center (US)
Inserm (FR)
Institut Gustave Roussy (FR)
Institut universitaire du cancer de Toulouse Oncopole (FR)
Centre Léon Bérard (FR)
Exact Sciences (United States) (US)
Institut Claudius Regaud (FR)
UniCancer Group (FR)
Clermont Université (FR)

Publication Details

Journal: European Journal of Cancer
Published: 2025-12-01
DOI: https://doi.org/10.1016/j.ejca.2025.116152
Primary Topic: Breast Cancer Treatment Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial

W. Fraser Symmans, Fabrice André, Thomas Filleron, Pascal Boucher et al.

Dec 1, 2025

European Journal of Cancer

Breast Cancer Treatment Studies

article

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial

W. Fraser Symmans, Fabrice André, Thomas Filleron, Pascal Boucher, Kevin C Tran, Magali Lacroix‐Triki, Amélie Lusque, Florence Dalenc, Frédérique Penault‐Llorca, Jérôme Lemonnier, Lili Du, Thomas Bachelot, Rick Baehner

December 1, 2025article en

Abstract

No abstract available for this paper.

European Journal of CancerVol. 233

The University of Texas MD Anderson Cancer Center (US), Inserm (FR), Institut Gustave Roussy (FR), Institut universitaire du cancer de Toulouse Oncopole (FR), Centre Léon Bérard (FR), Exact Sciences (United States) (US), Institut Claudius Regaud (FR), UniCancer Group (FR), Clermont Université (FR)

Openalex Percentile: Top 53%

Breast Cancer Treatment Studies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial — W. Fraser Symmans, Fabrice André, et al. · European Journal of Cancer (2025) | TGRS Research Map | TGRS